Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant PK in Hepatic Impairment
NCT05553470Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Mar 2022
- Primary completion
- Sep 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of miricorilant in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Corcept Therapeutics. Primary endpoints: Area Under the Concentration-Time Curve from Time Zero to Last Non-Zero Concentration, Area Under the Concentration-Time Curve from Time Zero to Infinity and 1 more. Started Mar 2022; status: completed.
02
Drugs
miricorilant
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05553470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553470.